- Home
- CHRS vs BZUN Comparison
CHRS vs BZUN Comparison
Compare CHRS & BZUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BZUN
- Stock Information
- Founded
- CHRS 2010
- BZUN 2007
- Country
- CHRS United States
- BZUN China
- Employees
- CHRS 235
- BZUN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BZUN Catalog/Specialty Distribution
- Sector
- CHRS Health Care
- BZUN Consumer Discretionary
- Exchange
- CHRS Nasdaq
- BZUN Nasdaq
- Market Cap
- CHRS 134.4M
- BZUN 188.7M
- IPO Year
- CHRS 2014
- BZUN N/A
- Fundamental
- Price
- CHRS $1.16
- BZUN $3.25
- Analyst Decision
- CHRS Strong Buy
- BZUN Strong Buy
- Analyst Count
- CHRS 4
- BZUN 3
- Target Price
- CHRS $5.38
- BZUN $3.20
- AVG Volume (30 Days)
- CHRS 2.4M
- BZUN 427.0K
- Earning Date
- CHRS 03-12-2025
- BZUN 03-20-2025
- Dividend Yield
- CHRS N/A
- BZUN N/A
- EPS Growth
- CHRS N/A
- BZUN N/A
- EPS
- CHRS N/A
- BZUN N/A
- Revenue
- CHRS $304,340,000.00
- BZUN $1,312,737,613.00
- Revenue This Year
- CHRS $2.47
- BZUN $8.16
- Revenue Next Year
- CHRS N/A
- BZUN $4.71
- P/E Ratio
- CHRS N/A
- BZUN N/A
- Revenue Growth
- CHRS 44.19
- BZUN 7.26
- 52 Week Low
- CHRS $0.66
- BZUN $2.11
- 52 Week High
- CHRS $2.87
- BZUN $4.38
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- BZUN 58.19
- Support Level
- CHRS $1.03
- BZUN $3.05
- Resistance Level
- CHRS $1.39
- BZUN $3.43
- Average True Range (ATR)
- CHRS 0.14
- BZUN 0.17
- MACD
- CHRS -0.03
- BZUN 0.03
- Stochastic Oscillator
- CHRS 14.04
- BZUN 74.26
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).